Multicentre phase II and pharmacokinetic study of RFS2000 (9-nitro-camptothecin) administered orally 5 days a week in patients with glioblastoma multiforme
- 1 July 2002
- journal article
- clinical trial
- Published by Elsevier in European Journal Of Cancer
- Vol. 38 (10) , 1348-1350
- https://doi.org/10.1016/s0959-8049(02)00070-9
Abstract
No abstract availableKeywords
This publication has 6 references indexed in Scilit:
- Irinotecan Therapy in Adults With Recurrent or Progressive Malignant GliomaJournal of Clinical Oncology, 1999
- A phase II clinical and pharmacological study of oral 9-nitrocamptothecin in patients with refractory epithelial ovarian, tubal or peritoneal cancerAnti-Cancer Drugs, 1999
- Survival rates for primary malignant brain tumours in EuropeEuropean Journal Of Cancer, 1998
- A phase I clinical and pharmacological study of oral 9-nitrocamptothecin, a novel water-insoluble topoisomerase I inhibitorAnti-Cancer Drugs, 1998
- Conversion of 9‐nitro‐camptothecin to 9‐amino‐camptothecin by human blood cells in vitroEuropean Journal of Haematology, 1994
- Response criteria for phase II studies of supratentorial malignant glioma.Journal of Clinical Oncology, 1990